Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 57

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 57
---
 |     | 2023 |     |            | 723,450 |     |              | 75,000 |     |                     | 1,269,620 |     |                   | 2,060,876 |     |                                        | 235,121 |     |                               |  11,058 |     |           | 4,375,125 |
| Amar Murugan                        |     | 2024 |     |            | 447,654 |     |              | 49,247 |     |                     |   266,000 |     |                   |         — |     |                                        |       — |     |                               | 115,527 |     |           |   878,428 |
| Former EVP, Chief Legal Officer     |     | 2023 |     |            | 515,000 |     |              | 50,000 |     |                     |   607,516 |     |                   |   986,132 |     |                                        | 141,947 |     |                               |  11,557 |     |           | 2,312,153 |

(1) Amounts reported in this column for 2024 consist of a bonus cash payment of in connection with the successful acceptance of our biologics license application (BLA) for tab-cel by the United States Food and Drug Administration (FDA). (2) The amounts in this column for 2024 reflect the aggregate fair value of RSUs awarded during the year, computed at the measurement date in accordance with Financial Accounting Standard Board Accounting Standards Codified (Topic 718) (“ASC 718”) based on the closing stock price on the date of grant. Pursuant to SEC rules, the amounts shown assume that there will be no service-based forfeitures of awards. Assumptions used in the calculation of these amounts are included in note 10 to our consolidated financial statements included in our Annual Report on Form 10-K for the year

<div align='center'>36</div>

ended December 31, 2024. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the RSUs or the sale of the common stock underlying such RSUs.

Amounts reported in this column for 2024 represent bonuses approved in February 2025 by the Human Capital Committee for fiscal year 2024 , but not yet paid, following the achievement of certain corporate goals as determined by the Board and as detailed